Impairment of insulin-stimulated Akt/GLUT4 signaling is associated with cardiac contractile dysfunction and aggravates I/R injury in STZ-diabetic Rats

Journal of Biomedical Science

Volumn 16, Issue 1, 2009, Pages

  Huang, Jiung Pang ^a   Huang, Shiang Suo ^b   Deng, Jen Ying ^a   Hung, Li Man ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE TRANSPORTER 4; INSULIN; PROTEIN KINASE B; AKT1 PROTEIN, RAT; SLC2A4 PROTEIN, RAT; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIASTOLE; DIASTOLIC DYSFUNCTION; DISEASE ASSOCIATION; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART OUTPUT; HEART RATE; HEMODYNAMICS; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; REPERFUSION INJURY; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES; SYSTOLIC DYSFUNCTION; VASCULAR RESISTANCE; ANIMAL; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; FORWARD HEART FAILURE; HEART CONTRACTION; INSULIN RESISTANCE; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN PROCESSING; PROTEIN TRANSPORT; SPRAGUE DAWLEY RAT;

ANIMALIA; RATTUS;

ANIMALS; CARDIAC OUTPUT, LOW; DIABETES MELLITUS, EXPERIMENTAL; GLUCOSE TRANSPORTER TYPE 4; HEART RATE; INSULIN; INSULIN RESISTANCE; MALE; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; STREPTOZOCIN;

EID: 70349937882     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-16-77     Document Type: Article

References (41)

1. Global and societal implications of the diabetes epidemic. P Zimmet KG Alberti J Shaw, Nature 2001 414 782 787 10.1038/414782a 11742409
2. Diabetes in America. LS Geiss WH Herman PJ Smith, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases 1995 233 257
3. Asymptomatic myocardial ischemia in diabetic patients. RW Nesto RT Phillips, Am J Med 1986 80 40 47 10.1016/0002-9343(86)90451-1 3706356
4. Myocardial insulin resistance and cardiac complications of diabetes. ED Abel, Curr Drug Targets Immune Endocr Metabol Disord 2005 5 219 226 10.2174/1568008054064869 16089356
5. Molecular analysis of insulin resistance in isolated ventricular cardiomyocytes of obese Zucker rats. T Kolter I Uphues J Eckel, Am J Physiol Endocrinol Metab 1997 273 59 E67
6. Effects of streptozotocin diabetes treatment by islet transplantation on in vivo insulin signaling in rat heart. L Laviola G Belsanti AM Davalli, Diabetes 2001 50 2709 2720 10.2337/diabetes.50.12.2709 11723053
7. Actions of insulin on the mammalian heart: metabolism, pathology and biochemical mechanisms. RW Brownsey AN Boone MF Allard, Cardiovasc Res 1997 34 3 24 10.1016/S0008-6363(97)00051-5 9217868
8. Insulin signaling in heart muscle: lessons from genetically engineered mouse models. ED Abel, Curr Hypertens Rep 2004 6 416 423 10.1007/s11906-004- 0034-4 15527684
9. Myocardial insulin resistance and cardiac complications of diabetes. ED Abel, Curr Drug Targets Immune Endocr Metabol Disord 2005 5 219 226 10.2174/1568008054064869 16089356
10. Insulin and myocardial blood flow. J Sundell J Knuuti, Cardiovasc Res 2003 57 312 319 10.1016/S0008-6363(02)00718-6 12566104
11. Insulin resistance in patients with hypertrophic cardiomyopthy. K Murakami Y Shigematsu M Hamada J Higaki, Circ J 2004 68 650 655 10.1253/circj.68.650 15226630
12. Role of hypertension, dyslipidemia and diabetes mellitus in the development of coronary atherosclerosis in japan. M Washio S Sasazuki H Kodama K Yoshimasu Y Liu K Tanaka, et al. Circ J 2001 65 731 737 10.1253/jcj.65.731 (Pubitemid 32744096)
13. Diabetes, hypertension, and cardiovascular disease: an update. JR Sowers M Epstein ED Frohlich, Hypertension 2001 37 1053 1059 11304502
14. Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. M Diamant HJ Lamb Y Groeneveld EL Endert JW Smit JJ Bax, et al. J Am Coll Cardiol 2003 42 328 335 10.1016/S0735-1097(03)00625-9 12875772
15. Diabetes and idiopathic cardiomyopathy: a nationwide case-control study. AG Bertoni A Tsai EK Kasper FL Brancati, Diabetes Care 2003 26 2791 2795 10.2337/diacare.26.10.2791 14514581
16. Regulation of glucose transporter and hexokinase-II expression in tissues of diabetic rats. R Burcelin RL Printz J Kande R Assan DK Granner J Girard, Am J Physiol 1993 265 392 E401 8214048
17. Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes. LM Hung JK Chen SS Huang RS Lee MJ Su, Cardiovasc Res 2000 47 549 555 10.1016/S0008-6363(00)00102-4 10963727
18. Beneficial effects of astringinin, a resveratrol analogue, on the ischemia and reperfusion damage in rat heart. LM Hung JK Chen RS Lee HC Liang MJ Su, Free Radic Biol Med 2001 30 877 883 10.1016/S0891-5849(01)00474-9 11295530
19. The Lambeth Convention: guidelines for the study of arrhythmias in ischemia, infarction and reperfusion. MJ Walker MJ Curtis DJ Hearse RW Campbell MJ Janse DM Yellon, et al. Cardiovasc Res 1988 22 447 455 10.1093/cvr/22.7.447 3252968
20. The mechanism of the tetrazolium reaction in identifying experimental myocardial infarction. HH Klein S Puschmann J Schaper W Schaper, Virchows Arch Pathol Anat 1981 393 287 297 (Pubitemid 11031537)
21. Endocannabinoids acting at CB1 receptors regulate cardiovascular function in hypertension. S Batkai P Pacher D Osei-Hyiaman S Radaeva J Liu J Harvey-White, et al. Circulation 2004 110 1996 2002 10.1161/01.CIR.0000143230. 23252.D2 15451779
22. Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. P Pacher L Liaudet P Bai JG Mabley PM Kaminski L Virag, et al. Circulation 2003 107 896 904 10.1161/01.CIR.0000048192.52098.DD 12591762
23. Impairment of cardiac insulin signaling and myocardial contractile performance in high-cholesterol/fructose-fed rats. JY Deng JP Huang LS Lu LM Hung, Am J Physiol Heart Circ Physiol 2007 293 978 H987 10.1152/ajpheart.01002. 2006 17400720
24. Adipocytes exhibit abnormal subcellular distribution and translocation of vesicles containing glucose transporter 4 and insulin-regulated aminopeptidase in type 2 diabetes mellitus: implications regarding defects in vesicle trafficking. L Maianu SR Keller WT Garvey, J Clin Endocrinol Metab 2001 86 5450 5456 10.1210/jc.86.11.5450 11701721
25. Physiological roles of PKB/Akt isoforms in development and disease. B Dummler BA Hemmings, Biochem Soc Trans 2007 35 231 235 10.1042/BST0350231 17371246
26. Akt2 regulates cardiac metabolism and cardiomyocyte survival. B DeBosch N Sambandam C Weinheimer M Courtois AJ Muslin, J Biol Chem 2006 281 32841 32851 10.1074/jbc.M513087200 16950770
27. Actions of insulin on the mammalian heart: metabolism, pathology and biochemical mechanisms. RW Brownsey AN Boone MF Allard, Cardiovasc Res 1997 34 3 24 10.1016/S0008-6363(97)00051-5 9217868
28. Insulin signaling in heart muscle: lessons from genetically engineered mouse models. ED Abel, Curr Hypertens Rep 2004 6 416 423 10.1007/s11906-004- 0034-4 15527684
29. The diabetic heart: metabolic causes for the development of a cardiomyopathy. B Rodrigues JH McNeill, Cardiovasc Res 1992 26 913 922 10.1093/cvr/26.10.913 1486584
30. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. PJ Randle PB Garland CN Hales EA Newsholme, Lancet 1963 1 785 789 10.1016/S0140-6736(63)91500-9 13990765
31. Left ventricular dysfunction and remodeling in streptozotocin-induced diabetic Rats. O Nemoto M Kawaguchi H Yaoita K Miyake K Maehara Y Maruyama, Circ J 2006 70 327 334 10.1253/circj.70.327 16501301
32. Pathogenesis of cardiac dysfunction in diabetes mellitus. NS Dhalla GN Pierce IR Innes RE Beamish, Can J Cardiol 1985 1 263 281 3850773
33. Glucose transport in the heart. ED Abel, Front Biosci 2004 9 201 215 10.2741/1216 14766360
34. Insulin signalling in the heart. L Bertrand S Horman C Beauloye JL Vanoverschelde, Cardiovasc Res 2008 79 238 248 10.1093/cvr/cvn093 18390897
35. Regulation of sarcolemmal glucose and fatty acid transporters in cardiac disease. RW Schwenk JJ Luiken A Bonen JF Glatz, Cardiovasc Res 2008 79 249 258 10.1093/cvr/cvn116 18469026
36. No-flow ischemia inhibits insulin signaling in heart by decreasing intracellular pH. C Beauloye L Bertrand U Krause AS Marsin T Dresselaers F Vanstapel, Circ Res 2001 88 513 519 11249875
37. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. P Ferdinandy R Schulz GF Baxter, Pharmacol Rev 2007 59 418 458 10.1124/pr.107.06002 18048761
38. Diabetic cardiomyopathy revisited. S Boudina ED Abel, Circulation 2007 115 3213 3223 10.1161/CIRCULATIONAHA.106.679597 17592090
39. Effects of alloxan-induced diabetes on ischemia-reperfusion injury in rabbit hearts. WM Vogel CS Apstein, Circ Res 1988 62 975 982 3359580
40. Acute myocardial infarction in dogs with experimental diabetes. R Forrat L Sebbag N Wiernsperger J Guidollet S Renaud M de Lorgeril, Cardiovasc Res 1993 27 1908 1912 10.1093/cvr/27.11.1908 8287395
41. Streptozotocin-induced non-insulin-dependent diabetes protects the heart from infarction. Y Liu JD Thornton MV Cohen JM Downey SW Schaffer, Circulation 1993 88 1273 1278 8353889